Ticker

JUPITER, Fla., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (NASDAQ: DYAI) (the “Company”), d/b/a Dyadic Applied BioSolutions, a biotechnology company developing recombinant protein solutions across the life sciences, food and nutrition, bio-industrial and biopharmaceutical markets, today announced definitive agreements with an institutional investor for the purchase and sale of shares of Common…

Dyadic International, Inc. (DYAI) Q2 2026 Earnings Call Transcript

JUPITER, Fla., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), d/b/a Dyadic Applied BioSolutions, a global biotechnology company producing precision-engineered, animal-free proteins and enzymes for diverse commercial applications, today reported its financial results for the second quarter ended June 30, 2026, highlighting significant…

Dyadic International (NASDAQ: DYAI - Get Free Report) and Myriad Genetics (NASDAQ: MYGN - Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, dividends, valuation and institutional ownership. Earnings and Valuation This table compares Dyadic

JUPITER, Fla., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (Nasdaq: DYAI) ("Dyadic" or the "Company"), d/b/a Dyadic Applied BioSolutions, a biotechnology company developing recombinant protein solutions across the life sciences, food & nutrition, bioindustrial and biopharmaceutical markets, today announced the expansion of its commercial non-animal dairy pipeline through a new development and…